PDCD1 and primary cutaneous T-cell non-Hodgkin lymphoma: Consistent with studies of Hodgkin lymphoma47, bladder cancer53, and glioblastoma78, our data suggest that CD4+ T cells, and particularly the PD-1+ CD4+ T cell subset, are crucial effectors that influence pembrolizumab response in CTCL.